PDF herunterladen
CC BY-NC 4.0 · Arch Plast Surg 2013; 40(06): 676-686
DOI: 10.5999/aps.2013.40.6.676
Original Article

Latent Transforming Growth Factor-beta1 Functionalised Electrospun Scaffolds Promote Human Cartilage Differentiation: Towards an Engineered Cartilage Construct

Erh-Hsuin Lim
Department of Materials and Institute of Biomedical Engineering, Imperial College London, London, UK
The Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
,
Jose Paulo Sardinha
Department of Materials and Institute of Biomedical Engineering, Imperial College London, London, UK
Instituto Superior Técnico and ICEMS, Lisbon, Portugal
,
Simon Myers
The Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
,
Molly Stevens
Department of Materials and Institute of Biomedical Engineering, Imperial College London, London, UK
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Background To overcome the potential drawbacks of a short half-life and dose-related adverse effects of using active transforming growth factor-beta 1 for cartilage engineering, a cell-mediated latent growth factor activation strategy was developed incorporating latent transforming growth factor-β1 (LTGF) into an electrospun poly(L-lactide) scaffold.

Methods The electrospun scaffold was surface modified with NH3 plasma and biofunctionalised with LTGF to produce both random and orientated biofunctionalised electrospun scaffolds. Scaffold surface chemical analysis and growth factor bioavailability assays were performed. In vitro biocompatibility and human nasal chondrocyte gene expression with these biofunctionalised electrospun scaffold templates were assessed. In vivo chondrogenic activity and chondrocyte gene expression were evaluated in athymic rats.

Results Chemical analysis demonstrated that LTGF anchored to the scaffolds was available for enzymatic, chemical and cell activation. The biofunctionalised scaffolds were non-toxic. Gene expression suggested chondrocyte re-differentiation after 14 days in culture. By 6 weeks, the implanted biofunctionalised scaffolds had induced highly passaged chondrocytes to re-express Col2A1 and produce type II collagen.

Conclusions We have demonstrated a proof of concept for cell-mediated activation of anchored growth factors using a novel biofunctionalised scaffold in cartilage engineering. This presents a platform for development of protein delivery systems and for tissue engineering.

Keywords

Transforming growth factor beta1 - Guided tissue regeneration - Biomimetics - Tissue scaffolds - Cartilage

The concept of this article has been granted an international (WO/2009/144457) and a US patent (US20110123592).


This article was presented at the Society of Academic Research Surgery on Jan 6, 2010 in London, UK and BAPRAS Winter Scientific Meeting on December 5, 2008 in London, UK. This study was awarded the Gibson Prize for the best paper presented at SARS 2010.




Publikationsverlauf

Eingereicht: 03. Juni 2013

Angenommen: 05. September 2013

Artikel online veröffentlicht:
01. Mai 2022

© 2013. The Korean Society of Plastic and Reconstructive Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonCommercial License, permitting unrestricted noncommercial use, distribution, and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes. (https://creativecommons.org/licenses/by-nc/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • REFERENCES

  • 1 Sohier J, Moroni L, van Blitterswijk C. et al. Critical factors in the design of growth factor releasing scaffolds for cartilage tissue engineering. Expert Opin Drug Deliv 2008; 5: 543-566
    CrossrefPubMedGoogle Scholar
  • 2 Guerne PA, Sublet A, Lotz M. Growth factor responsiveness of human articular chondrocytes: distinct profiles in primary chondrocytes, subcultured chondrocytes, and fibroblasts. J Cell Physiol 1994; 158: 476-484
    CrossrefPubMedGoogle Scholar
  • 3 Pedrozo HA, Schwartz Z, Gomez R. et al. Growth plate chondrocytes store latent transforming growth factor (TGF)-beta 1 in their matrix through latent TGF-beta 1 binding protein-1. J Cell Physiol 1998; 177: 343-354
    CrossrefPubMedGoogle Scholar
  • 4 Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003; 116: 217-224
    CrossrefPubMedGoogle Scholar
  • 5 Saharinen J, Keski-Oja J. Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol Biol Cell 2000; 11: 2691-2704
    CrossrefPubMedGoogle Scholar
  • 6 Koli K, Saharinen J, Hyytiainen M. et al. Latency, activation, and binding proteins of TGF-beta. Microsc Res Tech 2001; 52: 354-362
    CrossrefPubMedGoogle Scholar
  • 7 Wakefield LM, Winokur TS, Hollands RS. et al. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J Clin Invest 1990; 86: 1976-1984
    CrossrefPubMedGoogle Scholar
  • 8 Saharinen J, Hyytiainen M, Taipale J. et al. Latent transforming growth factor-beta binding proteins (LTBPs): structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev 1999; 10: 99-117
    CrossrefPubMedGoogle Scholar
  • 9 Mierisch CM, Cohen SB, Jordan LC. et al. Transforming growth factor-beta in calcium alginate beads for the treatment of articular cartilage defects in the rabbit. Arthroscopy 2002; 18: 892-900
    CrossrefPubMedGoogle Scholar
  • 10 Janssens S, Roberts C, Smith EF. et al. Physical stability of ternary solid dispersions of itraconazole in polyethyleneglycol 6000/hydroxypropylmethylcellulose 2910 E5 blends. Int J Pharm 2008; 355: 100-107
    CrossrefPubMedGoogle Scholar
  • 11 Zhu Y, Gao C, Liu X. et al. Surface modification of polycaprolactone membrane via aminolysis and biomacromolecule immobilization for promoting cytocompatibility of human endothelial cells. Biomacromolecules 2002; 3: 1312-1319
    CrossrefPubMedGoogle Scholar
  • 12 Li WJ, Cooper Jr JA, Mauck RL. et al. Fabrication and characterization of six electrospun poly(alpha-hydroxy ester)-based fibrous scaffolds for tissue engineering applications. Acta Biomater 2006; 2: 377-385
    CrossrefPubMedGoogle Scholar
  • 13 Li WJ, Danielson KG, Alexander PG. et al. Biological response of chondrocytes cultured in three-dimensional nanofibrous poly(epsilon-caprolactone) scaffolds. J Biomed Mater Res A 2003; 67: 1105-1114
    PubMedGoogle Scholar
  • 14 Ball MD, Bonzani IC, Bovis MJ. et al. Human periosteum is a source of cells for orthopaedic tissue engineering: a pilot study. Clin Orthop Relat Res 2011; 469: 3085-3093
    CrossrefPubMedGoogle Scholar
  • 15 Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-1108
    CrossrefPubMedGoogle Scholar
  • 16 Strehl R, Schumacher K, de Vries U. et al. Proliferating cells versus differentiated cells in tissue engineering. Tissue Eng 2002; 8: 37-42
    CrossrefPubMedGoogle Scholar
  • 17 von der Mark K, Gauss V, von der Mark H. et al. Relationship between cell shape and type of collagen synthesised as chondrocytes lose their cartilage phenotype in culture. Nature 1977; 267: 531-532
    CrossrefPubMedGoogle Scholar
  • 18 Kypriotou M, Fossard-Demoor M, Chadjichristos C. et al. SOX9 exerts a bifunctional effect on type II collagen gene (COL2A1) expression in chondrocytes depending on the differentiation state. DNA Cell Biol 2003; 22: 119-129
    CrossrefPubMedGoogle Scholar
  • 19 Zhao Q, Eberspaecher H, Lefebvre V. et al. Parallel expression of Sox9 and Col2a1 in cells undergoing chondrogenesis. Dev Dyn 1997; 209: 377-386
    CrossrefPubMedGoogle Scholar
  • 20 Kawakami Y, Rodriguez-Leon J, Izpisua Belmonte JC. The role of TGFbetas and Sox9 during limb chondrogenesis. Curr Opin Cell Biol 2006; 18: 723-729
    CrossrefPubMedGoogle Scholar
  • 21 Stevens MM, Marini RP, Martin I. et al. FGF-2 enhances TGF-beta1-induced periosteal chondrogenesis. J Orthop Res 2004; 22: 1114-1119
    CrossrefPubMedGoogle Scholar
  • 22 Chadjichristos C, Ghayor C, Herrouin JF. et al. Down-regulation of human type II collagen gene expression by transforming growth factor-beta 1 (TGF-beta 1) in articular chondrocytes involves SP3/SP1 ratio. J Biol Chem 2002; 277: 43903-43917
    CrossrefPubMedGoogle Scholar
  • 23 Binette F, McQuaid DP, Haudenschild DR. et al. Expression of a stable articular cartilage phenotype without evidence of hypertrophy by adult human articular chondrocytes in vitro . J Orthop Res 1998; 16: 207-216
    CrossrefPubMedGoogle Scholar
  • 24 Moulharat N, Lesur C, Thomas M. et al. Effects of transforming growth factor-beta on aggrecanase production and proteoglycan degradation by human chondrocytes in vitro . Osteoarthritis Cartilage 2004; 12: 296-305
    CrossrefPubMedGoogle Scholar
  • 25 Chou CH, Cheng WT, Lin CC. et al. TGF-beta1 immobilized tri-co-polymer for articular cartilage tissue engineering. J Biomed Mater Res B Appl Biomater 2006; 77: 338-348
    Google Scholar